A multicenter therapeutic study of 1100 children with brucellosis

A 6-year multicenter therapeutic study was performed on 1100 children with brucellosis in order to compare several antibiotic combinations and duration of treatment. The patients were randomized to receive oral therapy with oxytetracycline, doxycycline, rifampin and trimethoprim-sulfamethoxazole (TM...

Full description

Saved in:
Bibliographic Details
Published inThe Pediatric infectious disease journal Vol. 8; no. 2; p. 75
Main Authors Lubani, M M, Dudin, K I, Sharda, D C, Ndhar, D S, Araj, G F, Hafez, H A, al-Saleh, Q A, Helin, I, Salhi, M M
Format Journal Article
LanguageEnglish
Published United States 01.02.1989
Subjects
Administration, Oral
Adolescent
Brucellosis - drug therapy
Child
Child, Preschool
Doxycycline - administration & dosage
Drug Administration Schedule
Drug Therapy, Combination - therapeutic use
Female
Humans
Infant
Infant, Newborn
Male
Multicenter Studies as Topic
Oxytetracycline - administration & dosage
Random Allocation
Rifampin - administration & dosage
Sulfamethoxazole - administration & dosage
Time Factors
Trimethoprim - administration & dosage
Online AccessGet more information

Cover

More Information
Summary:A 6-year multicenter therapeutic study was performed on 1100 children with brucellosis in order to compare several antibiotic combinations and duration of treatment. The patients were randomized to receive oral therapy with oxytetracycline, doxycycline, rifampin and trimethoprim-sulfamethoxazole (TMP/SMX) either alone or in combination with each other or combined with streptomycin or gentamicin injections. The patients were also randomized into three groups based on the duration of oral therapy: 500 patients were treated for 3 weeks; 350 for 5 weeks; and 250 for 8 weeks. When intramuscular aminoglycosides were used, streptomycin was given for 2 weeks and gentamicin for 5 days. In oral monotherapy oxytetracycline, doxycycline and rifampin showed comparable results with low relapse rates (less than or equal to 9%) and no statistically significant differences were found among 3-, 5- or 8-week durations of therapy. TMP/SMX alone showed an unacceptably high relapse rate (30%) with all durations of therapy. In combined oral therapy rifampin plus oxytetracycline, rifampin plus TMP/SMX and oxytetracycline plus TMP/SMX showed comparable results with low relapse rates ranging from 4 to 8% in patients receiving therapy for 3 or 5 weeks, no relapses occurred in patients treated for 8 weeks. When oral monotherapy was combined with either streptomycin or gentamicin, very few relapses were seen, irrespective of the duration of treatment.
ISSN:0891-3668